,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 1998', 'fs': 'Oct 1998', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pIhUAI'}, 'Id': 'a0P2P0000050pIhUAI', 'Event_Date__c': '1998-10-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Oct 1998', 'Status_History__c': 'a132P000000ApPfQAK'}, 'change': None}]",Oct 1998,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""font-size: 14px;"">Medium priority for contraception, high priority for heavy menstrual bleeding (menorrhagia)</span></p>', 'fs': '<p><span style=""font-size: 14px;"">Medium priority for contraception, high priority for heavy menstrual bleeding (menorrhagia)</span></p>', 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': '<p><span style=""color: rgb(62, 62, 60);"">The Committee/Subcommittee reviewed the funding application for Levonorgestrel intrauterine system in the treatment of Contraception - long acting reversible contraception. The Committee/Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</span></p>', 'fs': '<p><span style=""color: rgb(62, 62, 60);"">The Committee/Subcommittee reviewed the funding application for Levonorgestrel intrauterine system in the treatment of Contraception - long acting reversible contraception. The Committee/Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</span></p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 1999', 'fs': 'Feb 1999', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 25 February 1999.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 25 February 1999.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pIiUAI'}, 'Id': 'a0P2P0000050pIiUAI', 'Event_Date__c': '1999-02-25', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 25 February 1999.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Feb 1999', 'Published_Recommendation__c': '<p><span style=""font-size: 14px;"">Medium priority for contraception, high priority for heavy menstrual bleeding (menorrhagia)</span></p>', 'Published_Application__c': '<p><span style=""color: rgb(62, 62, 60);"">The Committee/Subcommittee reviewed the funding application for Levonorgestrel intrauterine system in the treatment of Contraception - long acting reversible contraception. The Committee/Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</span></p>', 'Status_History__c': 'a132P000000ColFQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""font-size: 14px;"">Medium priority for contraception, high priority for heavy menstrual bleeding (menorrhagia)</span></p>', 'fs': '<p><span style=""font-size: 14px;"">Medium priority for contraception, high priority for heavy menstrual bleeding (menorrhagia)</span></p>', 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': '<p><span style=""color: rgb(62, 62, 60);"">The Committee/Subcommittee reviewed the funding application for Levonorgestrel intrauterine system in the treatment of Contraception - long acting reversible contraception. The Committee/Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</span></p>', 'fs': '<p><span style=""color: rgb(62, 62, 60);"">The Committee/Subcommittee reviewed the funding application for Levonorgestrel intrauterine system in the treatment of Contraception - long acting reversible contraception. The Committee/Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</span></p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 1999', 'fs': 'May 1999', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 20 May 1999.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 20 May 1999.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pIjUAI'}, 'Id': 'a0P2P0000050pIjUAI', 'Event_Date__c': '1999-05-20', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 20 May 1999.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'May 1999', 'Published_Recommendation__c': '<p><span style=""font-size: 14px;"">Medium priority for contraception, high priority for heavy menstrual bleeding (menorrhagia)</span></p>', 'Published_Application__c': '<p><span style=""color: rgb(62, 62, 60);"">The Committee/Subcommittee reviewed the funding application for Levonorgestrel intrauterine system in the treatment of Contraception - long acting reversible contraception. The Committee/Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</span></p>', 'Status_History__c': 'a132P000000ColGQAS'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended the listing of one hormonal Long Acting Reversible Contraception (LARC) on the Community Schedule, and noted that any of the currently available forms of hormonal LARC (including levonorgestrel intrauterine systems) would be acceptable.', 'fs': 'The Subcommittee recommended the listing of one hormonal Long Acting Reversible Contraception (LARC) on the Community Schedule, and noted that any of the currently available forms of hormonal LARC (including levonorgestrel intrauterine systems) would be acceptable.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-hormone-and-contraceptive-subcommittee-minutes-2009-05.pdf "" target=""_blank"">Hormone and Contraceptive Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-hormone-and-contraceptive-subcommittee-minutes-2009-05.pdf "" target=""_blank"">Hormone and Contraceptive Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2009', 'fs': 'May 2009', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Hormone and Contraceptive Subcommittee at meeting Friday 1 May 2009.', 'fs': 'Clinical advice received from Hormone and Contraceptive Subcommittee at meeting Friday 1 May 2009.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pIkUAI'}, 'Id': 'a0P2P0000050pIkUAI', 'Event_Date__c': '2009-05-01', 'Event_Description__c': 'Clinical advice received from Hormone and Contraceptive Subcommittee at meeting Friday 1 May 2009.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-hormone-and-contraceptive-subcommittee-minutes-2009-05.pdf "" target=""_blank"">Hormone and Contraceptive Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee recommended the listing of one hormonal Long Acting Reversible Contraception (LARC) on the Community Schedule, and noted that any of the currently available forms of hormonal LARC (including levonorgestrel intrauterine systems) would be acceptable.', 'Formatted_Date__c': 'May 2009', 'Status_History__c': 'a132P000000ApPnQAK'}, 'change': None}, {'Summary': {'s': 'PTAC noted and accepted the minutes of the Subcomittee.', 'fs': 'PTAC noted and accepted the minutes of the Subcomittee.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-08.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-08.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2009', 'fs': 'Aug 2009', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2009.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2009.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKIUAY'}, 'Id': 'a0P2P0000050pKIUAY', 'Event_Date__c': '2009-08-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2009.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2009-08.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'PTAC noted and accepted the minutes of the Subcomittee.', 'Formatted_Date__c': 'Aug 2009', 'Status_History__c': 'a132P000000ApTZQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/notification-2010-07-01-levonorgestrel.pdf "" target=""_blank"">Document</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/notification-2010-07-01-levonorgestrel.pdf "" target=""_blank"">Document</a>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2010', 'fs': 'Jul 2010', 'change': None}, 'Event_Description': {'s': 'PHARMAC under Delegated Authority has resolved to list the levonorgestrel implant Jadelle from 1 August 2010, and to approve a contract making Jadelle the sole subsidised Long Acting Reversible Contraceptive (LARC) until 31 December 2013. Because of this decision, no levonorgestrel intrauterine system may be funded until that time. This proposal will remain inactive until the sole supply period draws to a close.', 'fs': 'PHARMAC under Delegated Authority has resolved to list the levonorgestrel implant Jadelle from 1 August 2010, and to approve a contract making Jadelle the sole subsidised Long Acting Reversible Contraceptive (LARC) until 31 December 2013. Because of this decision, no levonorgestrel intrauterine system may be funded until that time. This proposal will remain inactive until the sole supply period draws to a close.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKJUAY'}, 'Id': 'a0P2P0000050pKJUAY', 'Event_Date__c': '2010-07-01', 'Event_Description__c': 'PHARMAC under Delegated Authority has resolved to list the levonorgestrel implant Jadelle from 1 August 2010, and to approve a contract making Jadelle the sole subsidised Long Acting Reversible Contraceptive (LARC) until 31 December 2013. Because of this decision, no levonorgestrel intrauterine system may be funded until that time. This proposal will remain inactive until the sole supply period draws to a close.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/notification-2010-07-01-levonorgestrel.pdf "" target=""_blank"">Document</a>', 'Formatted_Date__c': 'Jul 2010', 'Status_History__c': 'a132P000000ApaxQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2014-07.pdf"" target=""_blank"">Reproductive and Sexual Health Subcommittee minutes</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2014-07.pdf"" target=""_blank"">Reproductive and Sexual Health Subcommittee minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2014', 'fs': 'Jul 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 28 July 2014.', 'fs': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 28 July 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKKUAY'}, 'Id': 'a0P2P0000050pKKUAY', 'Event_Date__c': '2014-07-28', 'Event_Description__c': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 28 July 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2014-07.pdf"" target=""_blank"">Reproductive and Sexual Health Subcommittee minutes</a></p>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Jul 2014', 'Status_History__c': 'a132P000000AqjAQAS'}, 'change': None}, {'Summary': {'s': 'The Committee noted and accepted the Subcommittee&#39;s recommendations relating to the levonorgestrel releasing intrauterine system (LIUS), Mirena, and further recommended that an application be submitted to PTAC for all LIUS indications.', 'fs': 'The Committee noted and accepted the Subcommittee&#39;s recommendations relating to the levonorgestrel releasing intrauterine system (LIUS), Mirena, and further recommended that an application be submitted to PTAC for all LIUS indications.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a></p>', 'fs': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2014', 'fs': 'Nov 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKLUAY'}, 'Id': 'a0P2P0000050pKLUAY', 'Event_Date__c': '2014-11-06', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a></p>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Committee noted and accepted the Subcommittee&#39;s recommendations relating to the levonorgestrel releasing intrauterine system (LIUS), Mirena, and further recommended that an application be submitted to PTAC for all LIUS indications.', 'Formatted_Date__c': 'Nov 2014', 'Status_History__c': 'a132P000000AqotQAC'}, 'change': None}, {'Summary': {'s': '<p><span style=""color: rgb(62, 62, 60);"">The Subcommittee recommended that levonorgestrel intrauterine systems (LIUS) be listed on the Pharmaceutical Schedule with a high priority as a contraception option for women of reproductive age who are unable to use (due to contraindications) or tolerate (due to side effects) other LARCs.</span></p>', 'fs': '<p><span style=""color: rgb(62, 62, 60);"">The Subcommittee recommended that levonorgestrel intrauterine systems (LIUS) be listed on the Pharmaceutical Schedule with a high priority as a contraception option for women of reproductive age who are unable to use (due to contraindications) or tolerate (due to side effects) other LARCs.</span></p>', 'change': None}, 'Published_Recommendation': {'s': '<p>The Subcommittee recommended that levonorgestrel intrauterine systems (LIUS) be listed on the Pharmaceutical Schedule with a high priority as a contraception option for women of reproductive age who are unable to use (due to contraindications) or tolerate (due to side effects) other LARCs.\xa0</p>', 'fs': '<p>The Subcommittee recommended that levonorgestrel intrauterine systems (LIUS) be listed on the Pharmaceutical Schedule with a high priority as a contraception option for women of reproductive age who are unable to use (due to contraindications) or tolerate (due to side effects) other LARCs.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>Please refer to the full record of the meeting on the link below.</p>', 'fs': '<p>Please refer to the full record of the meeting on the link below.</p>', 'change': None}, 'Published_Application': {'s': '<p>The Subcommittee reviewed funding applications from four organisations: New Zealand Nurses Organisation (NZNO); Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG); Royal New Zealand College of General Practitioners (RNZCGP); and Family Planning New Zealand, for widened access to levonorgestrel intrauterine systems as a funded contraception option for all women of reproductive age.</p>', 'fs': '<p>The Subcommittee reviewed funding applications from four organisations: New Zealand Nurses Organisation (NZNO); Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG); Royal New Zealand College of General Practitioners (RNZCGP); and Family Planning New Zealand, for widened access to levonorgestrel intrauterine systems as a funded contraception option for all women of reproductive age.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2017-04.pdf"" target=""_blank"" style=""font-size: 14px; background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2017-04.pdf</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2017-04.pdf"" target=""_blank"" style=""font-size: 14px; background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2017-04.pdf</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2017', 'fs': 'Apr 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 10 April 2017.', 'fs': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 10 April 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKMUAY'}, 'Id': 'a0P2P0000050pKMUAY', 'Event_Date__c': '2017-04-10', 'Event_Description__c': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 10 April 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2017-04.pdf"" target=""_blank"" style=""font-size: 14px; background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/assets/ptac-reproductive-and-sexual-health-subcommittee-minutes-2017-04.pdf</a></p>', 'Outcome__c': 'High', 'Summary__c': '<p><span style=""color: rgb(62, 62, 60);"">The Subcommittee recommended that levonorgestrel intrauterine systems (LIUS) be listed on the Pharmaceutical Schedule with a high priority as a contraception option for women of reproductive age who are unable to use (due to contraindications) or tolerate (due to side effects) other LARCs.</span></p>', 'Formatted_Date__c': 'Apr 2017', 'Published_Recommendation__c': '<p>The Subcommittee recommended that levonorgestrel intrauterine systems (LIUS) be listed on the Pharmaceutical Schedule with a high priority as a contraception option for women of reproductive age who are unable to use (due to contraindications) or tolerate (due to side effects) other LARCs.\xa0</p>', 'Published_Application__c': '<p>The Subcommittee reviewed funding applications from four organisations: New Zealand Nurses Organisation (NZNO); Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG); Royal New Zealand College of General Practitioners (RNZCGP); and Family Planning New Zealand, for widened access to levonorgestrel intrauterine systems as a funded contraception option for all women of reproductive age.</p>', 'Published_Discussion__c': '<p>Please refer to the full record of the meeting on the link below.</p>', 'Status_History__c': 'a132P000000ColHQAS'}, 'change': None}, {'Summary': {'s': '<p>The Committee recommended that levonorgestrel intrauterine system (LIUS) for contraception be listed with a high priority.</p>', 'fs': '<p>The Committee recommended that levonorgestrel intrauterine system (LIUS) for contraception be listed with a high priority.</p>', 'change': None}, 'Published_Recommendation': {'s': '<p>The Committee recommended that Levonorgestrel Intrauterine System (LIUS) for the treatment of endometriosis in the community setting be listed with a high priority. The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>The Committee recommended that Levonorgestrel Intrauterine System (LIUS) for the treatment of endometriosis in the community setting be listed with a high priority. The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Committee considered funding applications from two health professional organisations for levonorgestrel intrauterine system (LIUS) to be funded in the community for endometriosis. The applications were from the Royal New Zealand College of General Practitioners, and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists. </p><p><br></p><p>The Committee noted that the funding applications were reviewed by the Reproductive and Sexual Health Subcommittee of PTAC at their April 2017 meeting.</p><p><br></p><p>The Committee noted the Subcommittee recommended that LIUS access be widened in the community, with a high priority, for women with endometriosis. </p><p><br></p><p>The Committee noted that LIUS 20mcg/day is currently funded for endometriosis in hospital, subject to the following restrictions: Initiation (endometriosis) only from an obstetrician or gynaecologist for patients meeting the following criterion: 1.1 The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy. Continuation (endometriosis) only from an obstetrician or gynaecologist for patients meeting the following criteria: Either: 1.1 Patient demonstrated satisfactory management of endometriosis; or 1.2 Previous insertion was removed or expelled within 3 months of insertion. Note: Endometriosis is an unregistered indication.</p><p><br></p><p>The Committee noted there is a range of funded pharmaceuticals that can be used for endometriosis; these include NSAIDs, oral contraceptives, depot medroxyprogesterone and oral progestogens. Members also noted that gonadotropinreleasing hormones are funded and used to manage endometriosis.</p><p><br></p><p>The Committee noted that while endometriosis is common, it is difficult to quantify prevalence as it can be asymptomatic, symptoms can vary and be non-specific, and definitive diagnosis can require direct visualisation of culprit lesions during open surgery or laparoscopy and/or biopsy, which are invasive procedures.</p><p><br></p><p>The Committee noted that pelvic pain is a key characteristic of endometriosis and is often the primary presenting symptom that patients seek medical help. Members also considered that unresolved pelvic pain can develop into chronic pain with consequent poor prognosis. The Committee noted the Brown et al. (2014) review of Cochrane systematic reviews for endometriosis, which showed evidence of a significant decrease in recurrence of painful menstruation in the LIUS group compared with the expectant management group (RR 0.22, 95% CI 0.08 to 0.60) in two trials (n = 95 women). Members also noted that in a third trial (n = 40) there was no evidence of significant difference in pain scores between the LIUS group and women who received gonadotropin-releasing hormones.</p><p><br></p><p>The Committee considered that the trial numbers in the review were low.</p><p><br></p><p>The Committee noted the Soini et al. (2014) study that found a reduced incidence of endometrial, pancreatic and lung cancers with use of LIUS for menorrhagia but an 20 increased incidence of breast cancer. Members noted the author’s conclusion that levonorgestrel-releasing intrauterine system may have a protective effect against endometrial malignant transformation. Members noted this study was about use of LIUS for menorrhagia, rather than endometriosis. While the Committee considered that this study is likely to be generalisable to NZ, the study design overlooked confounding factors such as parity, family history and other hormone use.</p><p><br></p><p>The Committee noted that the NICE clinical guideline on endometriosis (2017) recommends hormonal therapy (for example, the combined oral contraceptive or a progestogen) as an option for women with suspected, confirmed or recurrent endometriosis. Members also noted that the advice appears to be intentionally non-specific about which hormonal treatment; and further that the guideline advises that if initial hormonal treatment is not effective, not tolerated or is contraindicated, the patient should be referred to secondary services for investigation.</p><p><br></p><p>The Committee noted that in New Zealand, expert opinion and clinical practice supports the use of LIUS in primary care as both a trial intervention and diagnostic for endometriosis to reduce the burden on secondary care, in particular laparoscopy services. Members noted that this is consistent with the NICE 2017 guideline.</p><p><br></p><p>The Committee considered that there is an absence of good randomised controlled evidence for LIUS and comparators, including surgery, in the primary treatment of endometriosis. However, members noted that anecdotal evidence, expert opinion and clinical practice nationwide in the O&amp;G discipline supports the use of LIUS for endometriosis, and suggests it is effective for managing the symptoms of endometriosis, especially cyclical pain.</p><p><br></p><p>The Committee considered that there may be an unmet health need for women with chronic pelvic pain due to endometriosis and women with heavy menstrual bleeding who are unable to use copper IUD.</p><p><br></p><p>The Committee noted that the evidence for the health need of endometriosis is mixed. For period pain, the Committee considered that the evidence is of moderate quality but weak strength for clinical improvement.</p><p><br></p><p>The Committee noted moderate evidence for the reduction of long term cancer risk. The Committee also noted that the evidence for improvement of any other endometriosis symptoms is of poor quality and weak strength.</p><p><br></p><p>The Committee noted that use of LIUS for endometriosis is not a registered indication, however, members acknowledged that there is an established clinical use in NZ hospitals and it would be reasonable to fund LIUS in the community by listing it in Section B of the Pharmaceutical Schedule.</p><p><br></p><p>The Committee noted that widening access to LIUS for endometriosis in the community would increase demand for access to trained inserters in primary care. However, members considered that it is relatively easy to teach and learn how to insert LIUS in primary care.</p><p><br></p><p>The Committee considered that it would be clinically acceptable to fund either a three-year or five-year LIUS, and that any Medsafe approved brand would be suitable.</p><p><br></p><p>The Committee noted that training requirements would be the same regardless of brand.</p>', 'fs': '<p>The Committee considered funding applications from two health professional organisations for levonorgestrel intrauterine system (LIUS) to be funded in the community for endometriosis. The applications were from the Royal New Zealand College of General Practitioners, and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists. </p><p><br></p><p>The Committee noted that the funding applications were reviewed by the Reproductive and Sexual Health Subcommittee of PTAC at their April 2017 meeting.</p><p><br></p><p>The Committee noted the Subcommittee recommended that LIUS access be widened in the community, with a high priority, for women with endometriosis. </p><p><br></p><p>The Committee noted that LIUS 20mcg/day is currently funded for endometriosis in hospital, subject to the following restrictions: Initiation (endometriosis) only from an obstetrician or gynaecologist for patients meeting the following criterion: 1.1 The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy. Continuation (endometriosis) only from an obstetrician or gynaecologist for patients meeting the following criteria: Either: 1.1 Patient demonstrated satisfactory management of endometriosis; or 1.2 Previous insertion was removed or expelled within 3 months of insertion. Note: Endometriosis is an unregistered indication.</p><p><br></p><p>The Committee noted there is a range of funded pharmaceuticals that can be used for endometriosis; these include NSAIDs, oral contraceptives, depot medroxyprogesterone and oral progestogens. Members also noted that gonadotropinreleasing hormones are funded and used to manage endometriosis.</p><p><br></p><p>The Committee noted that while endometriosis is common, it is difficult to quantify prevalence as it can be asymptomatic, symptoms can vary and be non-specific, and definitive diagnosis can require direct visualisation of culprit lesions during open surgery or laparoscopy and/or biopsy, which are invasive procedures.</p><p><br></p><p>The Committee noted that pelvic pain is a key characteristic of endometriosis and is often the primary presenting symptom that patients seek medical help. Members also considered that unresolved pelvic pain can develop into chronic pain with consequent poor prognosis. The Committee noted the Brown et al. (2014) review of Cochrane systematic reviews for endometriosis, which showed evidence of a significant decrease in recurrence of painful menstruation in the LIUS group compared with the expectant management group (RR 0.22, 95% CI 0.08 to 0.60) in two trials (n = 95 women). Members also noted that in a third trial (n = 40) there was no evidence of significant difference in pain scores between the LIUS group and women who received gonadotropin-releasing hormones.</p><p><br></p><p>The Committee considered that the trial numbers in the review were low.</p><p><br></p><p>The Committee noted the Soini et al. (2014) study that found a reduced incidence of endometrial, pancreatic and lung cancers with use of LIUS for menorrhagia but an 20 increased incidence of breast cancer. Members noted the author’s conclusion that levonorgestrel-releasing intrauterine system may have a protective effect against endometrial malignant transformation. Members noted this study was about use of LIUS for menorrhagia, rather than endometriosis. While the Committee considered that this study is likely to be generalisable to NZ, the study design overlooked confounding factors such as parity, family history and other hormone use.</p><p><br></p><p>The Committee noted that the NICE clinical guideline on endometriosis (2017) recommends hormonal therapy (for example, the combined oral contraceptive or a progestogen) as an option for women with suspected, confirmed or recurrent endometriosis. Members also noted that the advice appears to be intentionally non-specific about which hormonal treatment; and further that the guideline advises that if initial hormonal treatment is not effective, not tolerated or is contraindicated, the patient should be referred to secondary services for investigation.</p><p><br></p><p>The Committee noted that in New Zealand, expert opinion and clinical practice supports the use of LIUS in primary care as both a trial intervention and diagnostic for endometriosis to reduce the burden on secondary care, in particular laparoscopy services. Members noted that this is consistent with the NICE 2017 guideline.</p><p><br></p><p>The Committee considered that there is an absence of good randomised controlled evidence for LIUS and comparators, including surgery, in the primary treatment of endometriosis. However, members noted that anecdotal evidence, expert opinion and clinical practice nationwide in the O&amp;G discipline supports the use of LIUS for endometriosis, and suggests it is effective for managing the symptoms of endometriosis, especially cyclical pain.</p><p><br></p><p>The Committee considered that there may be an unmet health need for women with chronic pelvic pain due to endometriosis and women with heavy menstrual bleeding who are unable to use copper IUD.</p><p><br></p><p>The Committee noted that the evidence for the health need of endometriosis is mixed. For period pain, the Committee considered that the evidence is of moderate quality but weak strength for clinical improvement.</p><p><br></p><p>The Committee noted moderate evidence for the reduction of long term cancer risk. The Committee also noted that the evidence for improvement of any other endometriosis symptoms is of poor quality and weak strength.</p><p><br></p><p>The Committee noted that use of LIUS for endometriosis is not a registered indication, however, members acknowledged that there is an established clinical use in NZ hospitals and it would be reasonable to fund LIUS in the community by listing it in Section B of the Pharmaceutical Schedule.</p><p><br></p><p>The Committee noted that widening access to LIUS for endometriosis in the community would increase demand for access to trained inserters in primary care. However, members considered that it is relatively easy to teach and learn how to insert LIUS in primary care.</p><p><br></p><p>The Committee considered that it would be clinically acceptable to fund either a three-year or five-year LIUS, and that any Medsafe approved brand would be suitable.</p><p><br></p><p>The Committee noted that training requirements would be the same regardless of brand.</p>', 'change': None}, 'Published_Application': {'s': '<p>The Committee reviewed the applications for levonorgestrel intrauterine system in the treatment of endometriosis.</p>', 'fs': '<p>The Committee reviewed the applications for levonorgestrel intrauterine system in the treatment of endometriosis.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<p><span style=""color: rgb(62, 62, 60);"">https://pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf</span></p>', 'fs': '<p><span style=""color: rgb(62, 62, 60);"">https://pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf</span></p>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKNUAY'}, 'Id': 'a0P2P0000050pKNUAY', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><span style=""color: rgb(62, 62, 60);"">https://pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf</span></p>', 'Outcome__c': 'High', 'Summary__c': '<p>The Committee recommended that levonorgestrel intrauterine system (LIUS) for contraception be listed with a high priority.</p>', 'Formatted_Date__c': 'Feb 2018', 'Published_Recommendation__c': '<p>The Committee recommended that Levonorgestrel Intrauterine System (LIUS) for the treatment of endometriosis in the community setting be listed with a high priority. The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Application__c': '<p>The Committee reviewed the applications for levonorgestrel intrauterine system in the treatment of endometriosis.</p>', 'Published_Discussion__c': '<p>The Committee considered funding applications from two health professional organisations for levonorgestrel intrauterine system (LIUS) to be funded in the community for endometriosis. The applications were from the Royal New Zealand College of General Practitioners, and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists. </p><p><br></p><p>The Committee noted that the funding applications were reviewed by the Reproductive and Sexual Health Subcommittee of PTAC at their April 2017 meeting.</p><p><br></p><p>The Committee noted the Subcommittee recommended that LIUS access be widened in the community, with a high priority, for women with endometriosis. </p><p><br></p><p>The Committee noted that LIUS 20mcg/day is currently funded for endometriosis in hospital, subject to the following restrictions: Initiation (endometriosis) only from an obstetrician or gynaecologist for patients meeting the following criterion: 1.1 The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy. Continuation (endometriosis) only from an obstetrician or gynaecologist for patients meeting the following criteria: Either: 1.1 Patient demonstrated satisfactory management of endometriosis; or 1.2 Previous insertion was removed or expelled within 3 months of insertion. Note: Endometriosis is an unregistered indication.</p><p><br></p><p>The Committee noted there is a range of funded pharmaceuticals that can be used for endometriosis; these include NSAIDs, oral contraceptives, depot medroxyprogesterone and oral progestogens. Members also noted that gonadotropinreleasing hormones are funded and used to manage endometriosis.</p><p><br></p><p>The Committee noted that while endometriosis is common, it is difficult to quantify prevalence as it can be asymptomatic, symptoms can vary and be non-specific, and definitive diagnosis can require direct visualisation of culprit lesions during open surgery or laparoscopy and/or biopsy, which are invasive procedures.</p><p><br></p><p>The Committee noted that pelvic pain is a key characteristic of endometriosis and is often the primary presenting symptom that patients seek medical help. Members also considered that unresolved pelvic pain can develop into chronic pain with consequent poor prognosis. The Committee noted the Brown et al. (2014) review of Cochrane systematic reviews for endometriosis, which showed evidence of a significant decrease in recurrence of painful menstruation in the LIUS group compared with the expectant management group (RR 0.22, 95% CI 0.08 to 0.60) in two trials (n = 95 women). Members also noted that in a third trial (n = 40) there was no evidence of significant difference in pain scores between the LIUS group and women who received gonadotropin-releasing hormones.</p><p><br></p><p>The Committee considered that the trial numbers in the review were low.</p><p><br></p><p>The Committee noted the Soini et al. (2014) study that found a reduced incidence of endometrial, pancreatic and lung cancers with use of LIUS for menorrhagia but an 20 increased incidence of breast cancer. Members noted the author’s conclusion that levonorgestrel-releasing intrauterine system may have a protective effect against endometrial malignant transformation. Members noted this study was about use of LIUS for menorrhagia, rather than endometriosis. While the Committee considered that this study is likely to be generalisable to NZ, the study design overlooked confounding factors such as parity, family history and other hormone use.</p><p><br></p><p>The Committee noted that the NICE clinical guideline on endometriosis (2017) recommends hormonal therapy (for example, the combined oral contraceptive or a progestogen) as an option for women with suspected, confirmed or recurrent endometriosis. Members also noted that the advice appears to be intentionally non-specific about which hormonal treatment; and further that the guideline advises that if initial hormonal treatment is not effective, not tolerated or is contraindicated, the patient should be referred to secondary services for investigation.</p><p><br></p><p>The Committee noted that in New Zealand, expert opinion and clinical practice supports the use of LIUS in primary care as both a trial intervention and diagnostic for endometriosis to reduce the burden on secondary care, in particular laparoscopy services. Members noted that this is consistent with the NICE 2017 guideline.</p><p><br></p><p>The Committee considered that there is an absence of good randomised controlled evidence for LIUS and comparators, including surgery, in the primary treatment of endometriosis. However, members noted that anecdotal evidence, expert opinion and clinical practice nationwide in the O&amp;G discipline supports the use of LIUS for endometriosis, and suggests it is effective for managing the symptoms of endometriosis, especially cyclical pain.</p><p><br></p><p>The Committee considered that there may be an unmet health need for women with chronic pelvic pain due to endometriosis and women with heavy menstrual bleeding who are unable to use copper IUD.</p><p><br></p><p>The Committee noted that the evidence for the health need of endometriosis is mixed. For period pain, the Committee considered that the evidence is of moderate quality but weak strength for clinical improvement.</p><p><br></p><p>The Committee noted moderate evidence for the reduction of long term cancer risk. The Committee also noted that the evidence for improvement of any other endometriosis symptoms is of poor quality and weak strength.</p><p><br></p><p>The Committee noted that use of LIUS for endometriosis is not a registered indication, however, members acknowledged that there is an established clinical use in NZ hospitals and it would be reasonable to fund LIUS in the community by listing it in Section B of the Pharmaceutical Schedule.</p><p><br></p><p>The Committee noted that widening access to LIUS for endometriosis in the community would increase demand for access to trained inserters in primary care. However, members considered that it is relatively easy to teach and learn how to insert LIUS in primary care.</p><p><br></p><p>The Committee considered that it would be clinically acceptable to fund either a three-year or five-year LIUS, and that any Medsafe approved brand would be suitable.</p><p><br></p><p>The Committee noted that training requirements would be the same regardless of brand.</p>', 'Status_History__c': 'a132P000000ColIQAS'}, 'change': None}]",Feb 1999,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKOUAY'}, 'Id': 'a0P2P0000050pKOUAY', 'Event_Date__c': '2018-02-14', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ApPsQAK'}, 'change': None}]",Feb 2018,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKPUAY'}, 'Id': 'a0P2P0000050pKPUAY', 'Event_Date__c': '2018-09-02', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000AsirQAC'}, 'change': None}]",Sep 2018,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-levonorgestrel-intrauterine-lius-systems-mirena-and-jaydess/"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-levonorgestrel-intrauterine-lius-systems-mirena-and-jaydess/"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2019', 'fs': 'Aug 2019', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKQUAY'}, 'Id': 'a0P2P0000050pKQUAY', 'Event_Date__c': '2019-08-29', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-levonorgestrel-intrauterine-lius-systems-mirena-and-jaydess/"" target=""_blank"">Consultation letter</a></p>', 'Formatted_Date__c': 'Aug 2019', 'Status_History__c': 'a132P000000Ask4QAC'}, 'change': None}]",Aug 2019,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2019', 'fs': 'Sep 2019', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKRUAY'}, 'Id': 'a0P2P0000050pKRUAY', 'Event_Date__c': '2019-09-17', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Sep 2019', 'Status_History__c': 'a132P000000AvhRQAS'}, 'change': None}]",Sep 2019,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-levonorgestrel-intrauterine-lius-systems-mirena-and-jaydess/"" target=""_blank"">Notification letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-levonorgestrel-intrauterine-lius-systems-mirena-and-jaydess/"" target=""_blank"">Notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000050pKSUAY'}, 'Id': 'a0P2P0000050pKSUAY', 'Event_Date__c': '2019-10-14', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-levonorgestrel-intrauterine-lius-systems-mirena-and-jaydess/"" target=""_blank"">Notification letter</a></p>', 'Formatted_Date__c': 'Oct 2019', 'Status_History__c': 'a132P000000B2F5QAK'}, 'change': None}]",Oct 2019,False,True
